REGN
Regeneron Pharmaceuticals, Inc. (REGN) Stock Valuation
Review Regeneron Pharmaceuticals, Inc. (REGN) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 20.78
- Price to book
- 2.6
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $95.87B
- Premium or discount
- -14.3%
- Market cap
- $82.16B
Regeneron Pharmaceuticals, Inc. (REGN) Stock Valuation research
The Regeneron Pharmaceuticals, Inc. valuation page presents the available multiples, profitability measures and BTI fair-value context for REGN. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.